Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 5:14:1152855.
doi: 10.3389/fimmu.2023.1152855. eCollection 2023.

Research progress in the development of natural-product-based mucosal vaccine adjuvants

Yingying Gao  1 , Ying Guo  1
Affiliations
Review

Research progress in the development of natural-product-based mucosal vaccine adjuvants

Yingying Gao et al. Front Immunol. .

Abstract

Mucosal vaccines have great potential and advantages in preventing infection caused by multiple pathogens. In developing mucosal vaccines, the biggest challenge comes from finding safe and effective adjuvants and drug delivery systems. Great progress has been made in the generation of mucosal adjuvants using detoxified bacterial toxin derivatives, pathogen-related molecules, cytokines, and various vaccine delivery systems. However, many problems, relating to the safety and efficacy of mucosal vaccine adjuvants, remain. Certain natural substances can boost the immune response and thus could be used as adjuvants in vaccination. These natural-product-based immune adjuvants have certain advantages over conventional adjuvants, such as low toxicity, high stability, and low cost of production. In this review, we summarize the latest natural-product-based immune adjuvants, and discuss their properties and clinical applications.

Keywords: adjuvants; mucosal vaccines; natural-product-based; polysaccharides; saponins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Paradigm of APS as Mucosal Immune Adjuvant. (i) Adjuvants are recognized by the TLR2 ligand of DCs and promote naive T differentiation. (ii) Th cells promote B cell differentiation into plasmacells which secrete IgA or IgG. (iii) DCs presents antigens that promote the transformation of CD8 cells into cytotoxic T lymphocytes (CTL).
See this image and copyright information in PMC

References

    1. Shao F, Yu D, Xia P, Wang S. Dynamic regulation of innate lymphoid cells in the mucosal immune system. Cell Mol Immunol (2021) 18(6):1387–94. doi: 10.1038/s41423-021-00689-6 - DOI - PMC - PubMed
    1. Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev BioMed Eng (2012) 14:17–46. doi: 10.1146/annurev-bioeng-071811-150054 - DOI - PubMed
    1. Neudecker V, Yuan X, Bowser JL, Eltzschig HK. Micrornas in mucosal inflammation. J Mol Med (Berl) (2017) 95(9):935–49. doi: 10.1007/s00109-017-1568-7 - DOI - PMC - PubMed
    1. Hansson GC. Mucins and the microbiome. Annu Rev Biochem (2020) 89:769–93. doi: 10.1146/annurev-biochem-011520-105053 - DOI - PMC - PubMed
    1. Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol (2022) 22(4):236–50. doi: 10.1038/s41577-021-00583-2 - DOI - PMC - PubMed

Publication types